Drawing for APRESTA

USPTO serial 77638654

APRESTA

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
Examiner
JOINER, KATINA JACKSON
Law office
OFFICE OF TRADEMARK PROGRAM CONTROL

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with APRESTA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, angiogenesis diseases and disorders, ocular diseases and disorders, and inflammatory diseases and disordersABANDONED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 22, 2009MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
Jun 22, 2009ABN5ABANDONMENT - AFTER PUBLICATION
Jun 2, 2009EXARTEAS EXPRESS ABANDONMENT RECEIVED
Apr 13, 2009ETOFEXTENSION OF TIME TO OPPOSE RECEIVED
Mar 17, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 25, 2009NPUBNOTICE OF PUBLICATION
Feb 10, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 10, 2009ALIEASSIGNED TO LIE
Jan 29, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jan 28, 2009DOCKASSIGNED TO EXAMINER
Dec 29, 2008NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance